ClinicalTrials.gg
Sign In
Drug

Platinum Compounds clinical trials

studies test it
26
open now
14
in phase 3
5
first study started
2004

How each study uses Platinum Compounds is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Platinum Compounds studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Platinum
7

In one entry with another drug

Given together, or one or the other

Platinum + Gemcitabine
2

Studies by the year they started

26 studies that test it; most in 2023 (4)

Studies that test Platinum Compounds, by start year
YearStudies
20041
20051
20091
20141
20163
20181
20201
20211
20223
20234
20241
20254
20264

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
13
Phase 3
5
Phase 4
2
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Small Cell Lung Carcinoma
5
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
2
Lung Neoplasms
1
Brain Neoplasms
1
Fallopian Tube Neoplasms
1
Head and Neck Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Adenocarcinoma of Lung
1
Gastrointestinal Neoplasms
1

Who runs them

Industry 5 · Other 21

Sun Yat-sen University (2) · China Medical University, China (2) · Peking Union Medical College Hospital (2) · Memorial Sloan Kettering Cancer Center (1) · Fudan University (1) · Bristol-Myers Squibb (1) · Shanghai Gynecologic Oncology Group (1) · Eli Lilly and Company (1)

Often tested with

Tested in the same studies.

Etoposide (3) · Bevacizumab (3) · Paclitaxel (3) · Pemetrexed (3) · Gemcitabine (3) · Anlotinib (3) · Tislelizumab (3) · Apatinib (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Platinum Compounds is the comparator. A study of two new drugs counts under both.

  • 1Ifebemtinib · InxMed (Shanghai) Co., Ltd. · next primary completion Sep 2028
  • 1Garsorasib · InxMed (Shanghai) Co., Ltd. · next primary completion Sep 2028
Reaching primary completion within a year · 4

Studies that test Platinum Compounds.

Studies

Open first, then newest update. How each study uses Platinum Compounds is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test Platinum Compounds →

Given beside what is tested · 20 — Platinum Compounds is usual care or a partner of the new treatment
As the comparator · 5 — what is tested is compared with Platinum Compounds

Codes

What other systems call Platinum Compounds · ClinicalTrials.gg INT008608

  • MeSH (NLM) D017671Platinum CompoundsOne source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.